Article
Oncology
Xun Wu, J. Ernesto Fajardo-Despaigne, Christine Zhang, Vishala Neppalli, Versha Banerji, James B. Johnston, Spencer B. Gibson, Aaron J. Marshall
Summary: In chronic lymphocytic leukemia (CLL), follicular helper T cells (T-FH) are increased and exhibit abnormal phenotypes with elevated levels of PD-1, TIGIT, CD40L, IFN gamma, and IL-21. Treatment with ibrutinib can normalize T-FH frequencies and phenotype. CLL development is associated with expansion of abnormal T-FH populations that produce elevated levels of cytokines and costimulatory molecules which may help support CLL proliferation.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Yueru Hou, Yejin Cao, Lin Dong, Yijin Huang, Zhiyuan Zhang, Yujing Bi, Guangwei Liu
Summary: Tfh cells play a crucial role in tumor immunity and their development is regulated at the DNA, RNA, and protein levels.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Immunology
Xiaomei Chen, Yulian Wang, Xin Huang, Suxia Geng, Chao Li, Lingji Zeng, Lisi Huang, Xin Du, Jianyu Weng, Peilong Lai
Summary: This study found that Bcl-6 inhibitor could prevent sclerodermatous chronic graft-versus-host disease in mice by inhibiting the function of T cells and the production of immunoglobulins, suggesting that Bcl-6 inhibition may be a potential treatment for patients with cGVHD.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Review
Immunology
Elisavet Vlachonikola, Kostas Stamatopoulos, Anastasia Chatzidimitriou
Summary: Chronic lymphocytic leukemia remains incurable despite recent progress in management, highlighting the importance of further investigating the underlying pathophysiology. The interactions between malignant CLL cells and the tumor microenvironment play a crucial role in disease progression, with T cell abnormalities and potential therapeutic targets being a key focus in enhancing targeted cytotoxic activity against the malignant clone.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Pharmacology & Pharmacy
Shengxia Yin, Jian Wang, Lin Chen, Minxin Mao, Rahma Issa, Yu Geng, Rui Huang, Xin Tong, Yong Liu, Chao Wu, Yuxin Chen, Jie Li
Summary: Failure to cure chronic hepatitis B virus (HBV) infection can impair B cell function. This study found that CTLA4 regulates B cell and T follicular helper (Tfh) cell differentiation, and that upregulation of CTLA4 in cTfh cells is associated with decreased HBsAg-specific resting memory B cells. Inhibition of CTLA4 restored HBsAb secretion and promoted plasma cell differentiation. These findings suggest that optimizing Tfh cell responses may lead to a functional cure for chronic HBV infection.
ANTIVIRAL RESEARCH
(2023)
Article
Multidisciplinary Sciences
Zuzana Mikulkova, Gayane Manukyan, Peter Turcsanyi, Milos Kudelka, Renata Urbanova, Jakub Savara, Eliska Ochodkova, Yvona Brychtova, Jan Molinsky, Martin Simkovic, David Starostka, Jan Novak, Ondrej Janca, Martin Dihel, Pavlina Ryznerova, Lekaa Mohammad, Tomas Papajik, Eva Kriegova
Summary: The tissue microenvironment in CLL plays a key role in the pathogenesis of this disease, with high inter-individual heterogeneity observed in the distribution and activation of immune cells depending on the bulk of CLL cells. High CLL counts were associated with low activation on circulating monocytes and T cells, while the highest activation of immune cells was seen in patients treated with novel agents.
SCIENTIFIC REPORTS
(2021)
Article
Cell Biology
Xiaoyu Cai, Meng Zhang, Fujia Ren, Weidong Fei, Xiao Zhang, Yunchun Zhao, Yao Yao, Nengming Lin
Summary: This study reveals the important role of synovial macrophage expression of OX40L in the differentiation of T follicular helper cells in the joint microenvironment, contributing to the pathogenesis of rheumatoid arthritis (RA).
Article
Cell Biology
Francesca Vittoria Sbrana, Benedetta Fiordi, Jessica Bordini, Daniela Belloni, Federica Barbaglio, Luca Russo, Lydia Scarfo, Paolo Ghia, Cristina Scielzo
Summary: Chronic Lymphocytic Leukaemia (CLL) is an incurable adult B-cell leukaemia, and targeting FAK and PYK2 may provide a potential therapeutic strategy for both CLL and its microenvironment. The overexpression of PYK2 in leukaemic B cells is significantly correlated with their malignant transformation. Inhibition of FAK and PYK2 with the specific inhibitor defactinib shows a dose-response effect on CLL cells viability and survival. In vivo treatment of a CLL mouse model demonstrates a decrease in the leukaemic clone and a reduction in macrophages, spleen weight, and size.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
(2023)
Review
Oncology
Elisavet Vlachonikola, Kostas Stamatopoulos, Anastasia Chatzidimitriou
Summary: The treatment of chronic lymphocytic leukemia (CLL) is continuously evolving, with immunotherapy emerging as a therapeutic option to boost immune responses against tumors. However, not all patients benefit from this approach, partly due to dysfunctional T cells in CLL. The tumor microenvironment (TME) is also crucial in impacting immune responses and tumor growth, highlighting the importance of understanding T cell defects and finding ways to overcome them for effective immunotherapy in CLL.
Article
Hematology
Jyoti Kumar, Mark D. Ewalt, Yanming Zhang, Jinjuan Yao, Meghan C. Thompson, Ahmet Dogan
Summary: This article describes the first reported cases of chronic lymphocytic leukaemia (CLL) patients with t(14;18)(q32;q21)/IGH::MALT1 translocation. Both patients in this report had lower-risk biological factors. Therefore, FISH testing for MALT1 should be implemented in clinical practice to better define cases with unknown IGH translocation partners in CLL.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Cell Biology
Michal K. Zarobkiewicz, Agnieszka A. Bojarska-Junak
Summary: CLL is the most common leukemia among adults, and currently there is no cure. Despite the dysfunction of gamma delta T cells in CLL patients, they can still be used for immunotherapy.
Article
Oncology
Xuan Lin, Longyun Ye, Xu Wang, Zhenyu Liao, Jia Dong, Ying Yang, Rulin Zhang, Hao Li, Pengcheng Li, Lei Ding, Tianjiao Li, Wuhu Zhang, Shuaishuai Xu, Xuan Han, Huaxiang Xu, Wenquan Wang, Heli Gao, Xianjun Yu, Liang Liu
Summary: The immunosuppressive microenvironment in PDAC is closely related to poor prognosis. Tfh cells promote an immunoactive tumor microenvironment by secreting CXCL13 and IL-21, correlating with better patient prognosis. However, the anti-tumor function of Tfh cells is inhibited by the PD-L1/PD-1 signaling pathway, which can be reversed by neoadjuvant chemotherapy.
Review
Immunology
Yanyan Liu, Yongping Song, Qingsong Yin
Summary: This review summarizes the effects of ibrutinib on the tumor microenvironment and cellular immunity in patients with CLL, particularly focusing on the behavior and function of T cells. The potential mechanisms of ibrutinib are explored, providing a basis for the clinical benefits of long-term ibrutinib treatment and combined therapy based on T-cell-based immunotherapies.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Jian Lu, Jing Wu, Xueli Xia, Huiyong Peng, Shengjun Wang
Summary: RA is a chronic autoimmune disease characterized by joint and systemic inflammation, with Tfh cells playing a crucial role in the pathogenesis of the disease and affecting disease activity.
CELLULAR AND MOLECULAR LIFE SCIENCES
(2021)
Article
Biochemistry & Molecular Biology
Valentina Rubino, Flavia Carriero, Anna Teresa Palatucci, Angela Giovazzino, Stefania Leone, Valerio Nicolella, Martina Calabro, Rosangela Montanaro, Vincenzo Brancaleone, Fabrizio Pane, Federico Chiurazzi, Giuseppina Ruggiero, Giuseppe Terrazzano
Summary: Chronic lymphocytic leukaemia (CLL) is characterized by the expansion of a neoplastic mature B cell clone. The clinical outcome of CLL is very heterogeneous, and it is influenced by genetic and epigenetic alterations and a pro-inflammatory microenvironment. The involvement of immune-mediated mechanisms in CLL control needs further investigation.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Letter
Hematology
Yixiang Chen, Chloe Peubez, Sandrine Jayne, Gabriella Kocsis-Fodor, Martin J. S. Dyer, Salvador Macip
BRITISH JOURNAL OF HAEMATOLOGY
(2019)
Letter
Hematology
Toby A. Eyre, Harriet S. Walter, Sunil Iyengar, George Follows, Matthew Cross, Christopher P. Fox, Andrew Hodson, Josh Coats, Santosh Narat, Nick Morley, Martin J. S. Dyer, Graham P. Collins
Article
Hematology
Nicolas Martinez-Calle, Sarah Hartley, Matthew Ahearne, Benjamin Kasenda, Amy Beech, Helen Knight, Constantine Balotis, Ben Kennedy, Simon Wagner, Martin J. S. Dyer, Dean Smith, Andrew K. McMillan, Fiona Miall, Mark Bishton, Christopher P. Fox
BRITISH JOURNAL OF HAEMATOLOGY
(2019)
Article
Multidisciplinary Sciences
Elliot Byford, Matthew Carr, Lucia Pinon, Matthew J. Ahearne, Simon D. Wagner
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS
(2019)
Article
Hematology
Ian W. Flinn, John G. Gribben, Martin J. S. Dyer, William Wierda, Michael B. Maris, Richard R. Furman, Peter Hillmen, Kerry A. Rogers, Swaminathan Padmanabhan Iyer, Anne Quillet-Mary, Loic Ysebaert, Harriet S. Walter, Maria Verdugo, Christian Klein, Huang Huang, Yanwen Jiang, Gerard Lozanski, Daniela Soriano Pignataro, Kathryn Humphrey, Mehrdad Mobasher, Thomas J. Kipps
Article
Multidisciplinary Sciences
Rebecca L. Allchin, Michael E. Kelly, Sami Mamand, Anthony G. Doran, Thomas Keane, Matthew J. Ahearne, Simon D. Wagner
Article
Oncology
Paurnima Patil, Agata Cieslak, Stephan H. Bernhart, Umut H. Toprak, Rabea Wagener, Cristina Lopez, Laura Wiehle, Susanne Bens, Janine Altmueller, Marek Franitza, Ingrid Scholz, Sandrine Jayne, Matthew J. Ahearne, Annika Scheffold, Billy M. C. Jebaraj, Christof Schneider, Dolors Costa, Till Braun, Alexandra Schrader, Elias Campo, Martin J. S. Dyer, Peter Nuernberg, Jan Duerig, Patricia Johansson, Sebastian Boettcher, Matthias Schlesner, Marco Herling, Stephan Stilgenbauer, Elizabeth Macintyre, Reiner Siebert
GENES CHROMOSOMES & CANCER
(2020)
Review
Hematology
Matthew A. Timmins, Simon D. Wagner, Matthew J. Ahearne
BRITISH JOURNAL OF HAEMATOLOGY
(2020)
Article
Oncology
Alexey V. Danilov, Charles Herbaux, Harriet S. Walter, Peter Hillmen, Simon A. Rule, Ebenezer A. Kio, Lionel Karlin, Martin J. S. Dyer, Siddhartha S. Mitra, Ping Cheng Yi, Rita Humeniuk, Xi Huang, Ziqian Zhou, Pankaj Bhargava, Juliane M. Jurgensmeier, Christopher D. Fegan
CLINICAL CANCER RESEARCH
(2020)
Article
Hematology
Barbara Ottolini, Nadia Nawaz, Christopher S. Trethewey, Sami Mamand, Rebecca L. Allchin, Richard Dillon, Paul A. Fields, Matthew J. Ahearne, Simon D. Wagner
Article
Oncology
Vincent Ribrag, Seung Tae Lee, David Rizzieri, Martin J. S. Dyer, Luis Fayad, Razelle Kurzrock, Leslie Andritsos, Reda Bouabdallah, Amjad Hayat, Larry Bacon, Yu Jiang, Kowser Miah, Bruno Delafont, Oday Hamid, Stephanie Anyanwu, Pablo Martinez, Brian Hess
Summary: Combination therapy with immune checkpoint inhibitors may enhance outcomes in patients with relapsed/refractory diffuse large B-cell lymphoma, but further evaluation is needed to clarify the role of anti-STAT3 agents in this setting.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2021)
Article
Hematology
Victoria M. Smith, Oliver Lomas, Donna Constantine, Lianne Palmer, Anna H. Schuh, David Bruce, Oksana Gonchar, Salvador Macip, Sandrine Jayne, Martin J. S. Dyer, Toby A. Eyre